Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

CONCLUSION: Bazedoxifene was recently approved for use in the European Union for the treatment of osteoporosis and thus may represent a near-term therapeutic option for patients with advanced breast cancer. Clin Cancer Res; 19(9); 2420-31. ©2013 AACR.
PMID: 23536434 [PubMed - in process]

Source: Clinical Breast Cancer - May 1, 2013 Category: Cancer & Oncology Authors: Wardell SE, Nelson ER, Chao CA, McDonnell DP Tags: Clin Cancer Res Source Type: research